BIOCURE TECHNOLOGY INC. (1WH) - Total Liabilities
Based on the latest financial reports, BIOCURE TECHNOLOGY INC. (1WH) has total liabilities worth €435.01K EUR (≈ $508.58K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does BIOCURE TECHNOLOGY INC. generate cash to assess how effectively this company generates cash.
BIOCURE TECHNOLOGY INC. - Total Liabilities Trend (2021–2025)
This chart illustrates how BIOCURE TECHNOLOGY INC.'s total liabilities have evolved over time, based on quarterly financial data. See BIOCURE TECHNOLOGY INC. net assets for net asset value and shareholders' equity analysis.
BIOCURE TECHNOLOGY INC. Competitors by Total Liabilities
The table below lists competitors of BIOCURE TECHNOLOGY INC. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PDG Realty S.A. Empreendimentos e Participações
SA:PDGR3
|
Brazil | R$3.98 Billion |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
Israel | ILA5.57 Million |
|
International Frontier Resources Corporation
V:IFR
|
Canada | CA$2.68 Million |
|
Rare Foods Australia Ltd
AU:RFA
|
Australia | AU$6.01 Million |
|
Mulberry Group PLC
LSE:MUL
|
UK | GBX100.94 Million |
|
Severfield PLC
LSE:SFR
|
UK | GBX203.49 Million |
|
Tearlach Resources Ltd
V:TEA
|
Canada | CA$1.02 Million |
|
Argo Blockchain PLC ADR
NASDAQ:ARBK
|
USA | $9.83 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down BIOCURE TECHNOLOGY INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of BIOCURE TECHNOLOGY INC..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOCURE TECHNOLOGY INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOCURE TECHNOLOGY INC. (2021–2025)
The table below shows the annual total liabilities of BIOCURE TECHNOLOGY INC. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €435.01K ≈ $508.58K |
-33.13% |
| 2024-12-31 | €650.57K ≈ $760.59K |
+74.30% |
| 2023-12-31 | €373.24K ≈ $436.36K |
-91.54% |
| 2022-12-31 | €4.41 Million ≈ $5.16 Million |
-11.87% |
| 2021-12-31 | €5.01 Million ≈ $5.85 Million |
-- |
About BIOCURE TECHNOLOGY INC.
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T … Read more